Role of Recombinant Proteins for Treating Rheumatoid Arthritis

Mahboubeh Soleimani  SasaniSasani; Yeganeh  Moradi

doi:10.18502/ajmb.v16i3.15739

Mahboubeh Soleimani SasaniSasani Shahid Beheshti University, Tehran, Iran
Yeganeh Moradi Department of Biotechnology Engineering, Faculty of Medical Engineering, Shahab Danesh University, Qom, Iran

DOI: https://doi.org/10.18502/ajmb.v16i3.15739

Keywords: Autoimmune diseases, Drug therapy, Recombinant proteins, Rheumatoid arthritis, Thera-peutic use

Abstract

Rheumatoid Arthritis (RA) is an autoimmune disease and chronic inflammatory disorder that affects joints and causes inflammation, pain, stiffness, and eventually progressive joint destruction. Approximately 1% of the world's population is estimated to suffer from RA, and if this disease is left untreated, it can lead to severe disability. Despite all the efforts and advances made by professionals in the field, there is currently no definitive treatment for RA, and most treatment strategies are aimed at relieving symptoms and improving patients' quality of life. One of the most promising current approaches is the use of recombinant proteins that target specific signaling pathways involved in the development of RA to alleviate symptoms and slow the progression of the disease. This article discusses the genetic and immunological factors that influence the development of RA, recombinant proteins, methods of using these proteins, approved drugs, and side effects associated with treating RA.